Good morning, ladies and gentlemen. My name is Sylvie. I will be your conference operator today. Welcome to BZAM Ltd.'s fourth quarter and full year 2022 conference call. To ensure an enjoyable experience for all participants, all lines have been placed on mute. Following the presentation, we will open the call for questions. If you would like to ask a question, simply press star then one. If you would like to withdraw your question please press star then two. Note that this call is being recorded on Monday May first 2023. I would like to turn the conference over to Mr. Matt Milich, Chief Executive Officer. Please go ahead, sir. Thank you, Sylvie. Good morning, and thank you all for joining us for our Q4 and full year 2022 conference call. Today, we will provide comments on our performance as well as an update on our operations and outlook. This call is being recorded, and the audio recording will be available on the company website at bzam.com. Joining me on the call this morning is Sean Bovingdon, our chief financial officer. Today's discussion includes forward looking statements. We caution that such statements are based on management's assumptions and beliefs and are subject to uncertainties and other factors that could cause actual results to differ materially. I refer you to our news release in MD&A for more information on these assumptions and factors. With that, I will now turn to the financial results and our outlook going forward. Fiscal 2022 was a transformational year that has laid a foundation for the years ahead. The BZAM transaction that was completed in November 2022 has ushered in a new chapter in the company's history. The enhanced scale expands revenue generation opportunities while also serving to reduce operating costs. The integration is nearly complete, and we have been pleased with the results to date. We have seen revenues grow materially and have crystallized the expected cost savings. As of December 2022, BZAM increased its recreational market share to 4.7% compared with 1.4% in December 2021, and has since surpassed 5% market share, making BZAM the 6th largest producer in Canada by share. The Q4 results were negatively impacted by one-time restructuring costs related to the BZAM transaction, as well as certain year-end provisions and revaluations. We expect to see the investment thesis come to fruition in the quarters ahead as the streamlined operations serve to decrease costs and increase margins. When paired with the substantially increased revenue resulting from the enhanced product suite and distribution synergies, we believe that our objective for positive adjusted EBITDA and free cash flow in fiscal 2023 remains intact. In fact, Q1 2023 has already demonstrated solid performance with approximately CAD 24 million in net revenue booked, representing nearly 40% growth from Q4 2022. Capital efficiency remains at the forefront of our strategic initiatives. During the year, management completed a comprehensive review of operations to reduce costs and identify revenue generation opportunities. Initiatives taken in 2022 include rightsizing headcount, minimizing reliance on third party service providers, and monetizing redundant assets. During 2022, we were pleased to complete all necessary steps to obtain EU GMP certification, with final approval now pending. The company has established strategic distribution partnerships for cannabis-derived medical products, and upon receiving final approval, we'll be able to execute on these relationships. With that, I will now hand the call over to Sean to take you through the Q4 financial results. Following this we will give some brief comments on the outlook for 2023 before taking questions. Thank you, Matt. Good morning, everyone. With that, just going through some of the financial results, starting off with our gross revenue, which for the three months ended December 31st 2022 was CAD 24.8 million, an increase of 100% compared to the same period in the prior year of CAD 12.4 million. Quarterly net revenues for the fourth quarter increased by 82% year-over-year to CAD 17.2 million. This strong growth was driven by an increased demand for our core SKUs, the introduction of new products, and enhanced distribution channels. Of note, excluding the impact of the BZAM acquisition from November 3rd BZAM brand's gross and net quarterly revenues increased by 28% and 21%, respectively, year-over-year. This underscores the value of combining the two growing companies with significant momentum and complementary revenue bases. The company's direct gross loss before changes in fair value of biological assets for Q4 2022 was CAD 2.7 million, representing a 15% direct gross loss margin. This loss was primarily driven, however, by non cash adjustments for inventory provisions and depreciation. Normalized direct gross profit, excluding these provisions, was CAD 3.5 million for the quarter, or 20%. This gross profit margin is expected to increase in 2023 as we increase capacity utilization and eliminate overheads connected to the redundant facilities that are currently held for sale. Cost control, as Matt mentioned, is a key focus for the company. As our team completed rigorous operational review during the year, and strides have been made across the company to improve profitability. Notably, in fiscal 2022, the adjusted SG&A was reduced to 57% of sales from 80% of sales in 2021. This continues to decrease as a percentage of sales in 2023. This was the result of rationalizing headcount, transitioning to a dedicated in-house salesforce team, and renegotiating our service level agreements with our vendors. The company ended the year with a net working capital position of CAD 45.4 million, an increase of 77% from December 2021. The increase from prior year was supported by the inclusion of the BZAM current assets, allowing fuller utilization of our existing revolving credit facility. We expect the company's liquidity position to be further enhanced as the assets held for sale are monetized in the year ahead. This stable capital position provides a platform to execute on opportunities, which we are seeing throughout the cannabis sector. With that, I'll pass it over to Matt again to discuss the outlook. Thanks, Sean. Before we move on to the Q&A, we would like to discuss the year ahead. The adult use cannabis market saw strong growth year-over-year, with consumers spending CAD 4.5 billion on products in 2022. Nearly 18% increase from the prior year. Statistics calling for another year of growth in 2023, with sales expected to grow by another 16% to CAD 5.2 billion. BZAM is well-positioned to take advantage of the growing adult use market. Company has doubled its portfolio of recognized brands to access a broader range of consumers. 2023 is off to a strong start, with quarterly net revenue expected to increase by nearly 40% from Q4 2022, reflecting the full quarter impact of the BZAM transaction and demonstrating the company's continued progress and growth. As I mentioned earlier on the call, a comprehensive operational review completed last year identified several opportunities to enhance revenue generation and streamline operations. This is outlined in detail in the MD&A. Some of these top initiatives include rightsizing the cultivation and manufacturing footprint to operate at higher capacity and thereby improve overhead absorption and increase profitability. In this regard, the company has exited the Valleyfield facility, commencing hash production in the smaller Beaudry facility in Quebec, and committed to sell the Maple Ridge and Puslinch assets. In addition, the company has developed a national operations strategy to improve efficiencies across all facilities, including building out a consolidated in-house sales team and optimizing freight by aggregation of shipments. Finally, the company has executed on procurement strategies achieved through the enhanced scale post-merger, resulting in improved purchasing and negotiating power. Our team has been hard at work building a company with a solid foundation for long-term value creation. We are committed to consistent improvements in product quality and efficiency of operations, using this as a guide for capital allocation decisions. We are very much looking forward to the opportunities in the year ahead. I would like to thank our employees for their dedication and hard work. I would also like to thank our shareholders for their continued support. With that, Sylvie, we are ready to take questions. Thank you, sir. Ladies and gentlemen, we will now begin the question-and-answer session. If you do have a question, please press star followed by one on your touchtone phone. You will hear a three tone prompt acknowledging your request. Your questions are pulled in the order they are received. If you are on a speakerphone, please lift the handset before pressing any keys. Your first question will be from Noel Atkinson at Clarus Securities. Please go ahead. Hi, good morning, Matt and Sean. Nice to see the revenues accelerating into Q1, and nice to see that you guys are finished your integration already. First off, on that point, can you just refresh our memory on, like, what is the dollar amount of cost savings that you folks have been able to crystallize? Now that the integration is complete, are you able to see all of that show up in the Q2 numbers, or does it still take until later in the year to start seeing the full impact of the cost savings? Sean, you wanna take that one? Certainly, yeah. The majority of the cost savings have been achieved in that Q4 and the early part of Q1, roughly almost CAD 10 million of annualized cost savings. As we crystallize the sale of Maple Ridge and Puslinch, as Matt mentioned, that removes some additional overhead. We do feel there'll be another half a million to CAD onef million dollars worth of savings still to come. Certainly in Q1 you'll see an impact on all the work that was done in Q4. In Q2, absolutely, we should see the by far the vast majority of the impact of that, and that leads towards that being towards that positive EBITDA that is our one of our main goals. Okay, great. Also just, you know, given the strong organic growth that you seem to be seeing, can you give us you know, for Q1, can you give us a sense of, you know, where you're seeing the strength in terms of geographies and product lines? That would be great. Thanks. Well, it's a great question, Noel. In fact, we're seeing the strength where we had hoped to see it, you know, originally going into the merger. For example, you know, we're having more success with some of the TGOD brand or TGOD and Highly Dutch brands in the West. We've had success getting some new SKUs into Quebec. Really, we're sort of seeing it across the board. Certainly, we're really pleased with sort of the continued strength and growth of the TGOD and the Highly Dutch brands. Great. All right. That's all for me. Thanks very much. Thank you. Once again, ladies and gentlemen, as a reminder, if you do have any questions, please press star followed by one on your touchtone phone. Your next question will be from Justin Dethier at Westcord Capital. Please go ahead. Hi. I'm curious what is going to remain with the Galaxy brands. It says you're selling some of it. Are you going to retain the Wyld Gummies and how are those selling? I'm here in Los Angeles, and they're very wildly popular, as one might say. How are they doing in Canada, and are you gonna keep the rights to those? Good question. Largely, well, let's start with Wyld. Wyld's terrific. You know, the product's terrific, the brand's terrific. Working with the folks, the team from the US has been a lot of fun. We've managed to migrate all the gummy production to a facility in British Columbia, where I think we're doing even, you know, better and we're having even more success on the manufacturing side. Yeah, the plan there is to continue going forward, and everyone's in alignment there. For the Galaxy brands themselves and the original Galaxy facility, that's sort of all being phased out. Gotcha. That would be the Cruzy brands and the, 'cause with the BZAM having infused pre-rolls and TGOD/Highly Dutch Organic, introduction of hash infused pre-rolls, it's just rationalizing that SKU and variability and being able to incorporate the type of products that Cruzy has into ness and the Highly Dutch Organic flower brands and pre-rolls already. I see. Thank you. Thank you. At this time, gentlemen, it appears that we have no other questions. Please proceed with closing remarks. Thank you, Sylvie. I just wanna thank everybody for joining us and, you know, as we said, we're looking forward to 2023 being a very exciting year for the new combined company. Thank you, sir. Ladies and gentlemen, this does conclude your conference call for today. Once again, thank you for attending. At this time, we do ask that you please disconnect your lines. Enjoy the rest of your day.